UPDATE: Jefferies Downgrades Epizyme (EPZM) to Hold

December 20, 2020 8:42 PM EST
Get Alerts EPZM Hot Sheet
Price: $4.51 +1.58%

Rating Summary:
    11 Buy, 3 Hold, 1 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 10 | Down: 8 | New: 36
Trade Now! 
Join SI Premium – FREE
(Updated - December 21, 2020 7:36 AM EST)

(updating comment)

Jefferies analyst Michael J. Yee downgraded Epizyme (NASDAQ: EPZM) from Buy to Hold with a price target of $14.00 (from $18.00).

The analyst comments "We move to Hold and believe the launch for Tazverik will grow but we are below consensus for 2021. Launch is progressing but there remain (1) logistical challenges of a launch during the pandemic, (2) headwinds from ASH COVID-19 guidelines specifically for indolent lymphomas (watch/wait protocol), and (3) investor uncertainties from competition (new biologics and feedback even on off label oral Ibrutinib) will need time to resolve."

For an analyst ratings summary and ratings history on Epizyme click here. For more ratings news on Epizyme click here.

Shares of Epizyme closed at $12.74 yesterday.

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst PT Change, Downgrades

Related Entities

Jefferies & Co